drugset
drugset / Trial / NCT00794443

ONO-5920/YM529 Confirmatory Study in Involutional Osteoporosis Patients

NCT00794443 ↗

Phase 2/3 Completed 692 enrolled Astellas Pharma Inc Ono Pharmaceutical Co., Ltd. · collab
RandomizedParallel-groupQuadruple-blindTreatment

Summary

This is a multi-center double-blind parallel-group study in involutional osteoporosis patients to compare the efficacy and safety of monthly oral intermittent formulation ONO-5920/YM529 with its daily formulation.

Timeline

Start
2008-11
Primary completion
2010-04
Completion
2010-04

Drugs

EvaluationDrugModalityDoseRoute
Subject Minodronic acid Small molecule — Oral

Indications

osteoporosis